Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 21, 2021

AstraZeneca selects Reify platform to accelerate clinical development

AstraZeneca has selected Reify Health’s patient enrolment management platform, StudyTeam, to accelerate clinical development across its portfolio of breast cancer investigational therapy.

AstraZeneca has selected Reify Health’s patient enrolment management platform, StudyTeam, to accelerate clinical development across its portfolio of breast cancer investigational therapy.

With the StudyTeam platform, AstraZeneca will also be able to alleviate the burden on research sites and improve patient matching for clinical trial enrolment worldwide.

The company has deployed Reify Health’s platform across several large global oncology clinical trials since 2019.

AstraZeneca decided to expand usage of StudyTeam due to high site engagement, supercharged workflows, and more visibility and control.

Reify Health CEO and co-founder Ralph Passarella said: “By empowering sites with easy-to-use technology that allows sites to manage patients across all trials, our technology enables AstraZeneca to overcome the traditional challenges of moving candidates effectively through the enrolment funnel.

“And as the sponsor, AstraZeneca is gaining real-time visibility into patient enrolment to make quick, informed decisions on key issues that reduce site burden, improve candidate identification, and ultimately accelerate enrolment timelines.”

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The StudyTeam platform expansion will include deployment of the Smart Patient Discovery feature.

Potential patients can be suggested to any research site coordinator using the StudyTeam system after obtaining information from a sponsor’s protocol.

This allows sites to effectively connect the right patient to the right trial.

In addition to AstraZeneca, Amgen and Eli Lilly and Company are using Reify Health’s StudyTeam to work with more than 3,000 research sites in over 100 countries.

Clinical research site Redlands Hematology Oncology senior data manager Katherine Wall said: “We now use StudyTeam to track patient recruitment and patient enrollment for all of our studies.

“StudyTeam is a huge game changer for us to track all our patients in the solid tumour and hematologic malignancy trials that we’re participating in, and we’re now able to be even more efficient with our prescreening, thanks to StudyTeam.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU